+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Grants Program

Cure Parkinsons Trust

This programme funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s. We do not fund research which is directed at symptomatic relief.Our grant funding process has changed! Due to the discontinuation of Grant Tracker, we will be returning to manual processes for research grant funding submissions. Please review all the guidance below for information on how to apply.Our funding remit

For preclinical research, we fund grants up to £250,000 (GBP) and prioritise projects that are likely to lead to clinical trials in people with Parkinson’s within 5 years. For clinical research, we fund clinical trials and sub-studies of trials in people with Parkinson’s. The grant amount is flexible but please contact us ahead of submission if you are thinking of applying for a clinical trial.

We fund internationally and accept applications from academics and commercial entities. However, the costs in commercial applications should be justified and equivalent to academic costs where possible.

How to apply for funding

Stage 1 applications should be submitted via email to research@cureparkinsons.org.uk.

All stage 1 application documents can be accessed at the bottom of this page, including:

Stage 1 application form
Drug and compound CV (if applicable)
Commercial entity form (if applicable)

Additional documents that can be included at this stage but are not mandatory and should be provided in their own format:

Principal investigator/Co-investigator CVs
Budget breakdown
Any supplementary documents to support the application (for example, further preliminary data, clinical trial protocol, publications)

Following Research Committee review of stage 1 applications, stage 2 applications will be invited on an individual basis and provided with the necessary documents via email.

The application process

Please review the guidance for applicants document below for more information about how to apply and the application and review process. If you have any questions regarding our funding scope, application process or subsequent work with successful applicants, please email the Research Team. Thank you.

AI Based Application Success Predictor

1️⃣ Focus on Disease Modification (Most Important Predictor)

Cure Parkinson’s funds only projects with credible disease-modifying potential.

Successful proposals:

Demonstrate mechanisms that could protect or restore dopaminergic neurons

Show modulation of pathways clearly linked to PD progression (e.g., α-synuclein, mitochondrial dysfunction, LRRK2, neuroinflammation, autophagy-lysosomal pathways)

Aim to slow progression, not reduce symptoms

Predictor: If the project is symptomatic-only, it will not be funded.

2️⃣ Strong Translational Rationale & Pathway to Clinical Use

Reviewers prioritize:

Proposals with a defined path to clinical trials

Studies that will produce data enabling IND-enabling steps or early-phase trials

High potential to rapidly move from bench → clinic

Partnerships with clinicians, trialists, or pharma/biotech

Predictor: High translational readiness is key.

3️⃣ Drug Repurposing → A Major Competitive Advantage

Because Cure Parkinson’s leads global drug repurposing efforts, high-scoring projects often:

Test already-approved drugs with plausible mechanisms for PD

Use computational, epidemiological, or mechanistic evidence supporting repurposing

Leverage safety data from other indications

Predictor: Repurposing proposals are often prioritized.

4️⃣ Strong Preliminary Data & Biological Plausibility

Competitive proposals include:

Mechanistic pilot studies

Preclinical efficacy in at least one PD model

Target validation evidence

Feasibility data for biomarkers or assays

Especially important for high-risk or novel mechanisms.

Predictor: Demonstrated feasibility increases confidence.

5️⃣ Use of Robust, Relevant Models

Cure Parkinson’s requires:

PD-relevant models (α-synuclein models, LRRK2, PINK1/Parkin, toxin models, iPSC-derived neurons)

Replication across more than one model if possible

Appropriate controls and rigorous experimental design

Predictor: Translatable, physiologically relevant models strongly impact scores.

6️⃣ Feasible, Milestone-Driven Design

Strong applications demonstrate:

Clear objectives over 12–36 months

Quantifiable milestones

Go/no-go decision points

Risk-mitigation strategies

Realistic budget and timelines

Predictor: Clarity and feasibility significantly matter.

7️⃣ Strong Investigative Team

Reviewers expect:

Expertise in PD biology and translational neuroscience

Team members with drug development or clinical trial experience

Access to specialized laboratory, imaging, and clinical infrastructure

A collaborative multidisciplinary approach

Predictor: Credible team with the capacity to deliver.

8️⃣ Clear Link to PD Progression Pathophysiology

Favorable topics include:

α-synuclein aggregation/spread

Neuroinflammation and microglial activation

Mitochondrial dysfunction

Oxidative stress pathways

Lysosomal/autophagy defects

Gut–brain axis mechanisms

LRRK2, GBA, and related genetic pathways

Predictor: Mechanistic relevance to PD progression.

9️⃣ Biomarker Integration

Cure Parkinson’s values biomarker development for:

Patient stratification

Target engagement

Progression measurement

Outcome sensitivity

Biomarker-ready proposals score higher.

🚫 COMMON PITFALLS (Why Cure Parkinson’s Applications Fail)

Pitfall	Why It Hurts
Symptomatic treatment (not disease-modifying)	Mission misalignment
Weak translational plan	Low probability of real-world impact
Insufficient preliminary data	High scientific risk
Poorly justified mechanism	Weak biological plausibility
Use of irrelevant or low-quality models	Low confidence in results
Overly ambitious design for short-term funding	Feasibility concerns
No biomarker strategy	Missing translational components
Lack of expertise in drug development or clinical translation	Execution risk

Specialties

Clinical Trials

Eligibility Requirements

This programme funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s.

Sponsor Details

Sponsor Institute/Organizations: Cure Parkinsons Trust

Sponsor Type: Corporate/Non-Profit

Address: 120 New Cavendish Street, London, W1W 6XX

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity